NU Hospital Group-Vaestra Goetalandsregionen
- Address
- lock Available on a paid plan
Bacterial Infections and Mycoses
The site is investigating alternative antibiotic strategies for infections caused by resistant bacteria, aiming to improve safety and effectiveness of outpatient care.
- Evaluation of oral step‑down regimens for multidrug‑resistant urinary tract infections
- Comparison of penicillin versus cloxacillin for Staphylococcus aureus bacteraemia
- Assessment of local antimicrobial agents in healing diabetic foot ulcers linked to bacterial infection
Collaboration with regional microbiology laboratories enhances pathogen identification and supports personalized therapy.
Cardiovascular Diseases
Research here targets innovative treatments for acute heart conditions, focusing on optimizing pharmacologic management to reduce complications.
- Investigation of adenosine‑based therapy for Takotsubo cardiomyopathy
- Study of apixaban versus no antithrombotic therapy to prevent thromboembolic events
- Evaluation of renin inhibition effects on renal involvement in cardiovascular patients
Findings are intended to inform clinical guidelines for emergency and chronic cardiac care.
Female Urogenital Diseases and Pregnancy Complications
The department conducts trials to enhance maternal health, with a focus on outpatient labour induction as a safe alternative to hospital admission.
- Randomized assessment of outpatient versus inpatient induction of labour
- Monitoring of maternal and fetal outcomes following novel induction protocols
Results aim to expand options for women seeking less invasive delivery preparations at NU Hospital Group‑Vaestra Goetalandsregionen.
Hemic and Lymphatic Diseases
Clinical studies address blood‑related cancers, seeking to improve survival through targeted maintenance therapies and combination regimens.
- Maintenance treatment comparison after autologous stem cell transplant in newly diagnosed multiple myeloma
- Evaluation of acalabrutinib plus rituximab in untreated mantle cell lymphoma
- Assessment of tafasitamab added to rituximab‑lenalidomide for follicular lymphoma
- Monotherapy trial of etentamig in relapsed or refractory multiple myeloma
The research supports personalized therapy pathways for patients with hematologic malignancies.
Hormonal diseases
Investigations focus on endocrine disorders, aiming to preserve organ function and improve quality of life through novel therapeutic approaches.
- Ixekizumab trial to preserve insulin secretion in newly diagnosed type 1 diabetes
- Aliskiren versus enalapril study in complement‑mediated C3 glomerulopathy
- Randomized evaluation of local antimicrobial dressings for diabetic foot ulcer healing
Outcomes may lead to new standards for managing hormonal and renal complications.
Immune System Diseases
The site explores immune‑mediated conditions, testing agents that modulate inflammation and enhance vaccine responses, with an emphasis on clinical efficacy and safety.
- Tezepelumab trial assessing histologic and symptom improvement in eosinophilic esophagitis
- Immunity assessment after revaccination against varicella and measles in childhood cancer survivors
- Evaluation of complement activation reduction in C3 glomerulopathy as an immune‑related kidney disease
Findings will contribute to better management of allergic, autoimmune, and post‑cancer immunologic health.
Neoplasms
Oncology research at the hospital targets a range of cancers, seeking to refine treatment based on molecular characteristics and disease stage.
- Adjuvant aspirin study in colorectal cancer patients with PIK3CA mutations
- Phase II trial for patients with recurrent non‑muscle invasive bladder cancer
- Pediatric cancer survivorship immunization monitoring
- Evaluation of tumor stage II‑III colon and rectal cancer outcomes
The work supports precision oncology initiatives across the Vaestra Goetalandsregionen.
Pathological Conditions, Signs and Symptoms
Studies address symptom relief and healing processes, aiming to accelerate recovery through targeted therapeutic interventions.
- Time‑to‑healing assessment of novel antimicrobial dressings for diabetic foot ulcers
- Symptom improvement measurement in eosinophilic esophagitis with tezepelumab
- Long‑term safety monitoring across multiple trial cohorts
Results are intended to guide clinicians in managing chronic and acute symptom burdens.
Virus Diseases
The clinical program includes investigations of viral infections, focusing on antiviral efficacy and neuroprotection.
- Remdesivir efficacy trial during tick‑borne encephalitis infection
- Neuronal injury biomarker analysis in viral encephalitis patients
Outcomes may influence treatment protocols for emerging viral encephalitic diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 52 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 51 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1Vaestra Goetalandsregionen5active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Vaestra Goetalandsregionen5trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in NU Hospital Group-Vaestra Goetalandsregionen
lock Showing 1 of 22 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) | Celgene Corp. | Phase III | Recruiting | Sep 2023 | — |
IMP list
lock Showing 1 of 52 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apixaban | 3 | Unknown | 2020-12-15 | 2023-09-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.